SRC inhibitors as potential therapeutic agents for human cancers.
Selective inhibitors of the Src family of protein tyrosine kinases have been developed as therapeutic agents for human tumors, some of which are now in various stages of clinical trial. In this review, recently described novel small molecule ATP-competitive Src inhibitors are discussed, with an emphasis on their potential use as therapeutic inhibitors for advanced-stage malignancies.
Trevino
Jose G
JG
University of Texas MD Anderson Cancer Center, Department of Cancer Biology, Houston TX 77054, USA.
Summy
Justin M
JM
Gallick
Gary E
GE
D000970:Antineoplastic Agents / Q000737:chemistry* / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D047428:Protein Kinase Inhibitors / Q000737:chemistry* / Q000627:therapeutic use*; D019061:src-Family Kinases / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000378:metabolism
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D019061:src-Family Kinases